Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Viatris Reaches $264m EpiPen Settlement Agreement With Trial Imminent

Company Admits No Wrongdoing; Maintains ‘That It Acted Lawfully’

Mar 02 2022

• By Dean Rudge

Gavel — Viatris' settlement must be ratified by the court • Source: Shutterstock: Chris Bain

Related Content

Viatris Plots January Investor Day To Flesh Out Longer-Term Roadmap

Nov 11 2021

Offloading Biosimilars To Biocon ‘First Step’ Towards Viatris’ $9bn Target

Mar 01 2022

US Court Dismisses Viatris EpiPen Suit, But Further Action Possible

Jul 29 2021

Related Companies

Viatris Inc.

Mylan Pharmaceuticals Inc.

Additional Topics

United States Deals Legal Issues Sales & Earnings Strategy BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.